EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia

Fang Cheng, Yu Wang, Yu Zhu, Yunfan Yang, Jianyu Weng, Na Xu, Jian Huang, Zhenfang Liu, Hongbo Ren, Huifang Zhao, Huanling Zhu, Yajuan Ke und 5 weitere

Journal of the National Comprehensive Cancer Network · 2026

DOI: 10.6004/jnccn.2026.7026 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026. Verfasst von Fang Cheng und 16 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment-free remission (TFR) has become a treatment goal for chronic myeloid leukemia (CML). This study aimed to define precise conditions for treatment discontinuation and to develop TFR prediction models in a Chinese population. Patients and Methods: This study collected data from 11 centers involving 802 cases of tyrosine kinase inhibitor (TKI) discontinuation in patients with CML. Eligible patients had received any TKI for at least 3 years and had maintained a deep molecular response (DMR) for at least 2 years. The primary endpoint was maintenance of major molecular response (MMR) within 12 months after discontinuation.

Results

Among 698 eligible patients (459 in the learning cohort and 239 in the validation cohort), 318 (45.6%) lost MMR, most commonly within the first 6 months after discontinuation (234/318; 73.6%). TFR rates were 66.5% at 6 months, 57.7% at 12 months, and 55.5% at 24 months. All patients regained MMR/DMR upon TKI reinitiation, with no disease progression. Longer treatment duration and sustained DMR were associated with higher TFR rates for both imatinib and second-generation TKIs. Superior outcomes correlated with low Sokal risk, no resistance, ≥5 years of TKI therapy, optimal DMR duration, and achievement of MMR at 12 months. The rate of sustained TFR was 73.5%, 60.0%, 44.6%, and 20.6% for patients with 0, 1, 2, and ≥3 nonoptimal factors, respectively. We developed predictive models and created a web-based calculator to assist clinicians in decision-making.

Conclusions

Patients achieving durable DMR can safely discontinue therapy with rigorous monitoring. TFR attempts remain viable even under nonoptimal conditions, provided that adequate DMR duration and close monitoring are maintained.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsHumansRemission InductionFemaleMaleMiddle AgedTreatment InterruptionAdultAgedTreatment Outcome

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • 2Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, Hubei, China.
  • 3Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • 4Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostic Group Co., Ltd., Hangzhou, Zhejiang, China.
  • 5Department of Hematology, Jiangsu Provincial People's Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • 6Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Zitieren

APA

Cheng, F., Wang, Y., Zhu, Y., Yang, Y., Weng, J., Xu, N., Huang, J., Liu, Z., Ren, H., Zhao, H., Zhu, H., Ke, Y., Wu, W., Du, X., Jiang, Q., Zhang, Y., & Li, W. (2026). Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2026.7026

Vancouver

Cheng F, Wang Y, Zhu Y, Yang Y, Weng J, Xu N, et al. Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2026.7026

BibTeX
@article{Cheng2026,
  author = {Cheng, Fang and Wang, Yu and Zhu, Yu and Yang, Yunfan and Weng, Jianyu and Xu, Na and Huang, Jian and Liu, Zhenfang and Ren, Hongbo and Zhao, Huifang and Zhu, Huanling and Ke, Yajuan and Wu, Weiyan and Du, Xin and Jiang, Qian and Zhang, Yanli and Li, Weiming},
  title = {Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  doi = {10.6004/jnccn.2026.7026}
}
Kostenlos starten →